Summary Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. In both plasma and KHT tumour the peak concentration and "early" AUC for total nitrosoureas were about 1.4-1.5 fold greater for the oral compared to the i.p. route. These differences were reflected in the roughly twofold greater antitumour activity for the oral route. In contrast, acute toxicity tests showed that oral CCNU was 1.45 times less toxic to normal tissue, although the dose-limiting organ may be different for the two routes. Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. Similarly, the acute toxicity was also diminished by a DMF of 0.74. Misonidazole has a complex effect on oral CCNU pharmacokinetics. The plasma and tumour total nitrosourea peak concentrations were reduced by 1.5 and 1.7 fold respectively. Misonidazole also reduced the "early" nitrosourea AUC, with the extent of the reduction depending on the minimum effective concentration (MEC) chosen. For example, the plasma nitrosourea AUC was reduced by factors of 1.05 and 9.6 for MEC values of 1 and 2pgml-1 respectively. We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
Chemosensitization of tumour response to cytotoxic agents by the nitroimidazole type of radiosensitizers is now well established (for review see McNally 1982; Siemann, 1984) . A number of clinical trials of the more promising combinations are presently in various stages of progress, e.g. misonidazole (MISO) plus melphalan (Coleman et al., 1983) , benznidazole plus CCNU (Roberts et al., 1984) and MISO plus CCNU (Siemann, personal communication) . Although the mechanism of nitroimidazole chemosensitization is still uncertain, it has become increasingly clear that changes in the pharmacokinetics of the cytotoxic agents by the sensitizers can play an important role (Tannock, 1980; Clutterbuck et al., 1982; Hinchliffe et al., 1983; Workman et al., 1983; Lee & Workman, 1983) . The most detailed studies in our laboratory have been carried out with the combination of MISO and CCNU in mice. We have shown that misonidazole reduces the plasma clearance of CCNU (Lee & Workman, 1983) probably through inhibition of hepatic drug metabolism (Lee & Workman, 1984b (Lee & Workman, 1984a) . We suggested that this effect of MISO is responsible for both the enhancement of tumour response and the improved therapeutic index for the combination as compared to that for CCNU alone (Lee & Workman, 1984a) .
However, in this previous work and in all other preclinical studies CCNU was given by the i.p. route, whereas the oral route is invariably used in the clinic. This unfortunate difference between experimental and clinical practice is particularly unsatisfactory since the pharmacokinetics of oral CCNU are likely to be quite different from those for other routes of administration because of the effects of extensive "first-pass" metabolism (Lee et al., In press). We have therefore investigated the effect of MISO on the antitumour effect, acute toxicity and pharmacokinetics of oral CCNU in mice. The present paper shows that the tumour and normal tissue toxicity of oral CCNU can be reduced by MISO. However, despite the seemingly contrasting effects of misonidazole for i.p. and oral CCNU, pharmacokinetic studies have shown them to be both the consequences of modified CCNU pharmacokinetics.
Materials and methods
Mice, tumour and acute toxicity testing Adult male C3H/He mice weighing between 25-35 g were used in all experiments. The KHT fibrosarcoma was grown in the gastrocnemius muscle as described by Twentyman et al. (1979) . Tumour bearing mice were treated when tumours were between 200-300mg. The time taken by individual tumours to reach 4 x their initial size was calculated and growth delay was the geometric mean of individual values in a group. Each group contained 7-9 mice. In acute toxicity studies, groups of 3-4 mice were treated with various doses of CCNU and the dose required to cause 50% lethality at 30 days (LD50/30) was determined by computerized probit analysis using the Generalized Linear Interactive Modelling Programme (GLIM) of the Royal Statistical Society of London.
Drug administration CCNU was first dissolved in a 1:1 mixture of ethanol/Cremophor-EL (Sigma). For oral administration this was diluted 2:3 with saline so that mice received 0.005mlg-1. Drug solution was delivered into the stomach lumen with an oraldosing cannula. For i.p. administration the dilution ratio was 1:4 and mice received at 0.01 m1g-1. MISO was dissolved in Hanks' balanced salt solution and injected in 0.04mlg-' i.p., at a dose 500 mgkg-1 (2.5 mmol kg-1), 0.5 h prior to CCNU. This dose of MISO has no effect on body temperature. Controls received the appropriate vehicles. Dose modifying factors (DMF) These were calculated from the equation: DMF = isoeffect dose for CCNU alone/isoeffect dose for CCNU plus MISO.
A DMF > 1 indicates an enhanced response (sensitization) while a DMF <1 indicates a reduced response (protection).
HPLC analysis
The HPLC method for the assay of CCNU and its metabolites as well as the preparative procedures for plasma and tumour samples were as described previously (Lee & Workman, 1983) , except that two columns in series were used instead of one for better resolution (for details see Lee et al., In press 65.2 (61.5-69 .2) for the oral route (0.01 > P > 0.002). This represents a difference of 1.45 fold. Interestingly whereas mice given oral CCNU died between 9-21 days (median 10 days), those that received CCNU i.p. died between 4-7 days (median 5 days). This difference in the time of death is suggestive of a change in the dose-limiting normal tissue for the two routes of administration. Plasma and tumour pharmacokinetics of oral CCNU: comparison with the i.p. route Orally administered CCNU is rapidly metabolised to monohydroxylated metabolites during the "first-pass" through the gut and the liver. The identities of these metabolites were found to be exactly the same as with i.p. CCNU (Lee & Workman, 1983) , namely trans-4-hydroxy CCNU, cis-4-hydroxy CCNU, cis-3-hydroxy CCNU, trans-3-hydroxy CCNU and trans-2-hydroxy CCNU. Their relative proportions were also the same with the cis-4-hydroxy and particularly the trans-4-hydroxy CCNU predominant. Only a small amount of parental CCNU appears systemically after oral CCNU. The peak plasma CCNU concentration after an oral dose of 20mgkg-t was 0.46pgml-l and represents only 5% of the peak concentration of total nitrosoureas (CCNU plus metabolites). Following i.p. CCNU, considerably more parent drug appeared in the plasma: the peak plasma concentration was approximately 4.0 pg ml -1, which represents about 60% of the peak plasma total nitrosourea concentration (Lee & Workman, 1983) . This is consistent with the idea that i.p. administered CCNU is absorbed rapidly, leading to a breakthrough of parent drug which escapes "firstpass" metabolism probably by saturating the microsomal enzymes. On the other hand, oral CCNU is probably absorbed more slowly; in consequence the liver metabolising enzymes are able to metabolize a larger proportion of the parent drug on its "first-pass". The second important difference between oral and i.p. CCNU is that the peak total nitrosourea concentrations were consistently -1.5 times higher for the former route, the values for plasma being Time (h) Figure 1 Comparison of the plasma total nitrosoureas pharmacokinetics for oral CCNU (closed symbols, solid line) and i.p. CCNU (broken line, no symbols; data from Lee & Workman, 1983) given at a dose of 20mg kg- (Siemann, 1981; Hirst et al., 1982; Workman & Twentyman, 1982; Lee & Workman, 1984a (Siemann 1981 (Siemann , 1982 Hirst et al., 1982) . The effects of MISO on the pharmacokinetic parameters of total nitrosoureas after oral CCNU are shown in Table II . To summarize, MISO reduced the plasma and tumour peak total nitrosourea concentration by factors of 1.5 and 1.7 respectively. In marked contrast, values for total nitrosourea AUCOG 0 were reduced only minimally, by factors of 1.05 and 1.1 for plasma and tumour respectively. This is because the reduction in AUC due to the lower and narrower peak was compensated for by the persistent plateau region of the elimination profile (Figure 4 ). Concentrations of CCNU required to give 1 log cell kill in vitro are in the range 2-30,jg ml-1 (summarized in Lee et al., In press), and Skipper et al. (1970) claimed that the minimum effective concentration (MEC) against L1210 cells was 2 Mg ml-1. Since the monohydroxylated metabolites of CCNU may be up to twice as toxic as the parent compound (Wheeler et al., 1977) , the nitrosourea AUC for concentrations 1-2 jg ml-1 might give a more realistic measure of effective cytotoxic exposure.
Because of its effect on peak concentration, MISO reduces these values to an extent which depends on the minimum effective concentration (MEC) chosen (Table III) . It can be seen that the lower the MEC is set the smaller the reduction of AUC becomes. For example, the plasma nitrosourea AUC was reduced by factors of 1.13 and 9.6 for MEC values of 1 and 2pgml-respectively.
It is significant that with MISO the early peak ( Figure 4 ) was composed largely of CCNU, the plasma concentration being 3.1 + 1.2 jg ml -1 (s.d.), which represents 50-60% of the peak total nitrosoureas, whereas in the controls the value was 0.46+0.05pgml-1 which was only -~5% of the peak.
Discussion
Although it has been shown previously that MISO can protect against the in vitro cytotoxicity of adriamycin and m-AMSA (West et al., 1981; Twentyman, 1982) , as far as we are aware this represents the first report of chemoprotection by MISO in vivo.
We have shown that MISO can clearly have two directly opposing effects on the activity of CCNU, depending on the route of administration of the cytotoxic agent. For i.p. CCNU, MISO has a sensitizing effect on tumour with little change in normal tissue response. On the other hand, MISO is protective when CCNU is given orally. The degree of protection appears to be similar in We previously showed that MISO reduces the clearance of i.p. CCNU, probably through inhibition of hepatic drug metabolising enzymes. In support of this mechanism we have shown that the same dose of MISO does inhibit drug metabolizing enzymes in mice (Workman et al., 1983 ) and more recently that pharmacological concentrations of MISO are able to inhibit the hydroxylation of CCNU by mouse liver microsomes (Lee & Workman, 1984b) . By overcoming the lag in drug penetration into the tumour this reduced clearance leads to a selective increase in peak nitrosourea concentration in the tumour but not in normal tissue, thus providing a pharmacokinetic mechanism for chemosensitization and therapeutic gain (Lee & Workman, 1983; 1984a; 1984b) . Furthermore, detailed studies of the effect of MISO on tumour and normal tissue CCNU pharmacokinetics suggested that .peak nitrosourea concentration and/or "early" AUC above a minimum effective concentration are the principle determinants of cytotoxicity (Lee & Workman, 1984a; Lee et al., In press ). The present paper shows that when CCNU is given orally, misonidazole reduces the peak nitrosourea concentration and "early" AUC, but not total AUC (AUCO a0), both in the plasma and the tumour, and we propose this to be the underlying mechanism for the reduction of oral CCNU cytotoxicity.
Comparing the pharmacokinetic parameters of oral with i.p. CCNU in the absence of MISO it is clear that although parent CCNU levels are actually lower following oral administration, both the total nitrosourea peak concentration and "early" AUC in the tumour are greater because of the higher concentration of metabolites. This finding explains the comparatively greater tumour response we have obtained for oral CCNU, particularly since the metabolites may be more active than the parent compound (Wheeler et al., 1977) . The difference in peak concentration may be at least partly due to the fact that absorption is slower by the oral route and the liver is able to convert more completely the parent CCNU to monohydroxylated metabolites. Since these metabolites are much more hydrophilic than the parent compound (Wheeler et al., 1977) (Lee & Workman, 1984a) and it may be that these are reduced when the drug is given orally. Further studies using specific assays for gut and bone marrow damage should allow the elucidation of the mechanism involved. The effect of MISO on oral CCNU pharmacokinetics is very complex. However the considerably higher peak levels of CCNU in the presence of MISO is a clear indication that the drug metabolising process is impaired by the sensitizer. Rapid distribution of the parent drug that has escaped "first-pass" metabolism would then explain the transient nature of the peak. The persistent plateau region of the total nitrosourea elimination profile, which immediately follows the initial peak, is made up almost entirely of the hydroxylated metabolites. The steady-state situation suggests that the rate of formation of the metabolites is equalled by their rate of clearance, the latter also being slowed by MISO as with the i.p. route (Lee & Workman, 1983) . It is significant that the clearance of total nitrosoureas returns to control level by -6 h. In previous experiments where i.p. CCNU was given at different intervals following the same dose of MISO we showed that the duration of pharmacokinetic modification was also about 6h, and this reflects the time taken for the circulating MISO to fall below the minimum effective concentrations of about 100-300pgml- (Workman, 1980; Lee & Workman, 1983) .
Whatever the precise mechanism of these major changes in pharmacokinetics, it is certain that the large reduction by MISO in both the plasma and tumour peak nitrosourea concentrations and "early" AUC, but not AUCOG 1 is the likely reason for the apparent reduction of CCNU cytotoxicity. Furthermore, this lends support to our proposal that AUCOG0 is comparatively less important than the other two parameters in determining the activity of nitrosoureas (Lee & Workman, 1984a) .
We should be extremely cautious when speculating on the possible clinical consequences of these findings. Not only have we shown here that the pharmacokinetics are different for the oral compared to the i.p. route in mice, and that this results in altered drug efficacy, toxicity and therapeutic ratio, but our recent clinical studies have also shown that the pharmacokinetics of oral CCNU in man exhibit additional differences from those with either route in the mouse (Lee et al., In press). What we can say is that MISO is able to act either as a chemosensitizer or as a chemoprotector depending on the nature of the alteration in CCNU pharmacokinetics. Furthermore, we know that these effects obtained with a relatively high dose MISO are not exclusively mouse phenomena, since equiactive doses of the more potent chemosensitizer benznidazole are well tolerated in patients (Roberts et al., in press ) and do produce marked changes in nitrosourea pharmacokinetics after oral CCNU (Roberts et al., in preparation) . We therefore strongly recommend that the use of such regimes in patients should be accompanied by detailed pharmacokinetic investigations.
